Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$4.62 USD
+0.14 (3.13%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.61 -0.01 (-0.22%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VNDA 4.62 +0.14(3.13%)
Will VNDA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VNDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VNDA
Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
VNDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know
Vanda Pharmaceuticals (VNDA) Declines More Than Market: Some Information for Investors
Other News for VNDA
Vanda Pharmaceuticals (VNDA) Shares Cross Below 200 DMA
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
Shareholder Capital delivers letter to board of Vanda Pharmaceuticals
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZĀ® ANDA Litigation
US Supreme Court reportedly declines to hear Vanda patent case